Hodgkin's Lymphoma Cancer News

Latest Hodgkin's Lymphoma Cancer News

Sun, 01 Nov 2009 14:59:26 +0100

Latest news for Hodgkin's Lymphoma Cancer updated every 30 minutes, dedicated for patients, caregivers, physicians and researchers whose interest are hodgkin's lymphoma, hodgkin's disease, lymphoma cancer.

Cancer Detection Lab Tests Online

Sun, 01 Nov 2009 14:59:26 +0100

Order cancer detection lab tests online safely and securely. Physicians Order Included. Always Secure. - Read more ...

Lymphoma Cancer Ribbon

Sun, 01 Nov 2009 14:59:26 +0100

Lymphoma Cancer Support Ribbon Lapel Pins. - Made in U.S.A. - Help Increase Lymphoma Cancer Awareness and Early Detection.

Vegetables reduce risk of non-Hodgkins lymphomas.

Non-Hodgkins lymphomas are cancers of the lymph nodes, spleen, and other components of the immune system. The incidence of non-Hodgkins lymphomas has increased over the past 25 years for unknown reasons. This type of cancer accounts for about 4 percent of all new cancer diagnoses and 3 percent of ...

Study Shows Durable Long-Term Responses in Non-Hodgkins Lymphoma Patients Treated With Zevalin.

SAN DIEGO, December 6 /PRNewswire/ - Research presented today at the American Society of Hematology 46th Annual Meeting indicates that Zevalin frequently produces durable long-term responses in patients with relapsed or refractory B-cell NHL. These data show that in ...

Updates: Can Primary Care MDs Manage TB?; SV-40 in Non-Hodgkins Lymphoma.

Updates By Carol A. Kemper, MD, FACP Can Primary Care MDs Manage TB? Source: LoBue PA, et al. Int J Tuberc Lung Dis. 2001;5:933-938. Community physicians are at the front lines in the battle against tuberculosis . They are often the first to recognize cases of active TB, and often ...

Genentechs Rituxan Has Generated Strong Growth in the NHL Market since Its Launch, Although Rituxans Market Penetration May Have Peaked - New Approaches To The Treatment Of Non-Hodgkins Lymphoma.

M2 PRESSWIRE-19 December 2006-Research and Markets: Genentechs Rituxan Has Generated Strong Growth in the NHL Market since Its Launch, Although Rituxans Market Penetration May Have Peaked - New Approaches To The Treatment Of Non-Hodgkins Lymphoma1994-2006 M2 COMMUNICATIONS LTD RDATE:21122006 ...

Simultaneous presentation of Hodgkins and follicular non-Hodgkins lymphoma in a previously healthy male.

A 53-year-old active duty male with no significant past medical history noted left sided inguinal lymphadenopathy while deployed in Bosnia that did not resolve over a 2-week period. He also noted mild night sweats for 1-2 months and a 15-pound weight loss over several months. An excisional lymph ...

Total Revenue for drugs treating non-Hodgkins lymphoma expected to grow to $4.7 billion by 2008.

M2 PRESSWIRE-23 December 2003-Research and Markets: Total Revenue for drugs treating non-Hodgkins lymphoma expected to grow to $4.7 billion by 2008.1994-2003 M2 COMMUNICATIONS LTD RDATE:12232003 Research and Markets announces the addition of this exciting new report entitled "Patterns and Trends ...

NON-HODGKINS LYMPHOMA

00-00-0000 THIS IS A RUSH TRANSCRIPT. THIS COPY MAY NOT BE IN ITS FINAL FORM AND MAY BE UPDATED. CHARLES GIBSON: King Hussein died of non-Hodgkins lymphoma, and not many of us know what that is. So our medical editor, Dr. Tim Johnson is joining us from Boston to tell us more about it. Tim, good to ...

Primary renal non-Hodgkins lymphoma presenting with acute renal failure

Primary renal lymphoma has been reported in medical literature. Its occurrence is rare and controversial, the kidney being an extranodal organ. We report a case of primary renal lymphoma presenting with acute-on-chronic renal failure and unilateral involvement of the left kidney without ...

Coulter Corporation and InterWest Partners form company to market new treatment for non-Hodgkins lymphoma.

PALO ALTO, CalifBUSINESS WIREMarch 27, 1995-Coulter Corporation and InterWest Partners announced they are forming a pharmaceutical company to market a promising new treatment for non-Hodgkins lymphoma. The company, called Coulter Pharmaceutical, Inc., will be headquartered in Palo Alto, Calif. Its ...

Tumor Cell Purging by High Density Microparticles Shows Favorable Phase I/II Results in Patients With Non-Hodgkins Lymphoma.

NEW ORLEANS, Dec. 6 /PRNewswire/ - Eligix, Inc. announced today the results of the first human clinical trial using a novel tumor cell purging technology that has promise for the treatment of patients suffering from B- cell malignancies such as non-Hodgkins lymphoma, who undergo bone marrow stem ...

Cancer Supplements

Sun, 01 Nov 2009 14:59:26 +0100

Discount Natural Cancer Supplements and Products and natural vitamin supplements at 20% to 70% off retail. Read more ...